India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India-focused Independent Equity Research Analyst

Experienced (7 years +) in Sector-Specific Deep Dives and Comprehensive Company Research.

With a sharp focus on the Indian market, I specialize in providing in-depth analysis and insights to investors. Whether it's dissecting various sectors to identify emerging trends or conducting thorough fundamental research on individual companies, I'm dedicated to uncovering valuable opportunities and delivering actionable intelligence.

Passionate about navigating the nuances of the Indian equity landscape, I thrive on deciphering complex market dynamics and distilling them into clear, concise insights. 

While covering a sector or company-specific research, I cover the following :
1. Brief about company/sector
2.  Overall Industry landscape - History, Present and Future trends
3. Thesis and Anti-Thesis
4. Valuations
5. Financial & Forensic Analysis
6. Management Review
7. Key Monitorable Events
8. Guidance and Future Way Ahead

India Equity Analyst - Fundamental & Thematic

Why India's Pharma Giants Are Betting on Chronic Business?

Zaynich Approvals: How Wockhardt Could Unlock a $7 Billion Opportunity

Thematic Report- Indian IT: AI Is Rewriting the Business Model

From Aroma to Alpha: Privi Speciality Chemicals Clears FY26 With Flying Colors

India Glycols: The Only Bio-Based Chemical Manufacturer in India!

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Derivatives

Dr. Reddy's Laboratories / Equity Derivatives

<ul>
<li>Dr. Reddy's Q4 FY26 PAT crashed 86% YoY to Rs 221 crore as lenalidomide exclusivity ended and North America revenues fell 51% in a single quarter.</li>
<li>The lenalidomide era is definitively over. FY27 earnings visibility now hinges almost entirely on semaglutide ramp-up, a molecule with first-mover approvals but uncertain revenue scale.</li>
<li>With Canada approved, India launched, and US BLA filed, the structural pivot is underway. But the pace of semaglutide uptake will determine whether FY27 is recovery or a prolonged trough.</li>
</ul>


Dr. Reddy's Q4 FY26 PAT crashed 86% YoY to Rs 221 crore as lenalidomide exclusivity ended and North America revenues fell 51% in a single quarter.
The lenalidomide era is definitively over. FY27 earnings visibility now hinges almost entirely on semaglutide ramp-up, a molecule with first-mover approvals but uncertain revenue scale.
With Canada approved, India launched, and US BLA filed, the structural pivot is underway. But the pace of semaglutide uptake will determine whether FY27 is recovery or a prolonged trough.


Dr. Reddy's: Lenalidomide Over, Semaglutide Start